28 Investor presentation First six months of 2025 Novo Nordisk holds solid patent p advantages Novo Nordisk’s position is protected by patents and value chain setup EU/US patent protection 1 2031/32 2 2031/2032 2,3 2030 4 2034/32 2 2028/29 2028/29 2028/29 2027/28 2036/34 1 List does not include all marketed products 2 Current estimates. Wegovy ® patent identical to Ozempic ® patent 3 Tablet formulation a ingredient patent has expired API: Active pharmaceutical ingredient; CAPEX: Capital expenditure; PD: Pharmacodynamic; PK: Pharmacokinetic; ROI: Return on inv
Download PDF file